Skip to main content
. 2022 Dec 19;21(4):374–385. doi: 10.1158/1541-7786.MCR-22-0474

Figure 5.

Figure 5. The immune landscape in paired PTs and their metastases. A, The TMB distribution of all 28 primary and metastatic samples. The total TMB (defined as the number of nonsynonymous mutations) in each group. B, Baseline comparison and characteristics of neoantigen counts in PTs and BMs. TNB, tumor neoantigen burden; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma. C, Percentage of shared and private neoantigens. D, The distribution of identified HLA genotype categories in the HLA complex. E, Corresponding HLA genotypes of clonal neoantigens. HLA: human leukocyte antigen.

The immune landscape in paired PTs and their metastases. A, The TMB distribution of all 28 primary and metastatic samples. The total TMB (defined as the number of nonsynonymous mutations) in each group. B, Baseline comparison and characteristics of neoantigen counts in PTs and BMs. TNB, tumor neoantigen burden; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma. C, Percentage of shared and private neoantigens. D, The distribution of identified HLA genotype categories in the HLA complex. E, Corresponding HLA genotypes of clonal neoantigens. HLA, human leukocyte antigen.